The molecular mechanism of etanercept, an anti-tumour necrosis factor-α receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis

Journal of Dermatological Treatment

Volumn 20, Issue 4, 2009, Pages 241-245

  Gencoglan, Gulsum ^a   Tosun, Murat ^b   Aktepe, Fatma ^b  

^a CELAL BAYAR UNIVERSITY MEDICAL FACULTY   (Turkey)

^b AFYON KOCATEPE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

AGEP; Apoptosis; bcl 2; Etanercept; p53; TNF

Indexed keywords

EMOLLIENT AGENT; ETANERCEPT; HYBRID PROTEIN; PREDNISOLONE; PROTEIN BCL 2; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CASE REPORT; CLINICAL EVALUATION; DRUG EFFICACY; DRUG MECHANISM; EPIDERMIS; FEMALE; FEVER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LABORATORY TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUSTULE; RASH; SKIN; SKIN BIOPSY;

ACUTE DISEASE; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN; SKIN DISEASES, VESICULOBULLOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69049091366     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802683843     Document Type: Article

References (17)

1. Roujeau JC, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, et al. Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol. 1991;127:1333-1338
2. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157:989-996 (Pubitemid 47583506)
3. Williams JDL, Griffiths CEM. Cytokine blocking agents in dermatology. Clin Exp Dermatol. 2002;27:585-590
4. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-726 (Pubitemid 46955730)
5. Saito K, Mori S, Tanda N, Sakamoto S. Expression of p53 protein and Ki-67 antigen in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontol. 1999;70:581-586 (Pubitemid 29284150)
6. Famularo G, Di Dona B, Canzona F, Girardelli CR, Cruciani G. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007;41:1083-1084
7. Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch WCh, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: Response to antitumour necrosis factor-alpha antibody infliximab: Report of three cases. J Eur Acad Dermatol Venereol. 2007;21:717-719 (Pubitemid 46916796)
8. Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85:534-535 (Pubitemid 43087298)
9. Lerch M, Pichler WJ. The immunological and clinical spectrum of delayed drug-induced exanthems. Curr Opin Allergy Clin Immunol. 2004;4:411-419 (Pubitemid 39274083)
10. Sidoroff A, Halevy S, Bavnick JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol. 2001;28:113-119 (Pubitemid 32112994)
11. De Coninck AL, Van Strubarq AS, Pipeleers-Marichal MA, Huyghens LP, Suys ET, Roseeuw DI. Acute generalized exanthematous pustulosis induced by paracetamol: A case with severe hemodynamic disturbances. Dermatology. 1996;193:338-341 (Pubitemid 27007582)
12. Scheinfeld N, Wesson K, Perry P, Weinberg J. Acute generalized exanthematous pustulosis resembling toxic epidermal necrolysis caused by famotidine. Acta Derm Venereol. 2003;83:76-77 (Pubitemid 36223070)
13. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI. In: Fitzpatrick's dermatology in general medicine. 6th ed. New York: McGraw-Hill; 2003. 625-627
14. Frederic JE, Nesbitt LT. Adverse cutaneous drug eruptions. In: Slaven EM, Stone SC, Lopez FA, editors. Infectious diseases: Emergency department diagnosis and management. 1st ed. New York: McGraw-Hill; 2007. 226-236
15. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;15:209:123-129
16. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116:923-924 (Pubitemid 41400562)
17. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146:707-709 (Pubitemid 34437794)